| 1 |
35081606 | Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients. | 2022 Jun 1 |
4 |
| 2 |
35396676 | Interactions with the CYP3A inhibitor voriconazole differ between extended-LCP- and immediate-release tacrolimus formulations. | 2022 Jun |
1 |
| 3 |
35589097 | Simultaneous Determination of Cortisol and 6β-Hydroxycortisol in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry. | 2022 May 20 |
1 |
| 4 |
33815119 | Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization. | 2021 |
1 |
| 5 |
33826998 | Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. | 2021 Jun |
1 |
| 6 |
33971831 | Severe secondary hyperkalemia and arrhythmia from drug interactions between calcium-channel blocker and voriconazole: a case presentation. | 2021 May 10 |
1 |
| 7 |
34069798 | Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats. | 2021 May 18 |
2 |
| 8 |
34402388 | Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies. | 2021 Oct |
8 |
| 9 |
31853755 | A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. | 2020 Jun |
8 |
| 10 |
32427354 | A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. | 2020 Sep |
1 |
| 11 |
33004392 | Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. | 2020 Oct 1 |
1 |
| 12 |
33124772 | Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections. | 2020 Dec |
1 |
| 13 |
30572203 | Development and validation of a volumetric absorptive microsampling assay for analysis of voriconazole and voriconazole N-oxide in human whole blood. | 2019 Jan 15 |
1 |
| 14 |
31152598 | Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers. | 2019 Dec |
2 |
| 15 |
28786218 | Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole". | 2018 Feb |
4 |
| 16 |
28786228 | Impact of CYP3A4 Genotype on Voriconazole Exposure. | 2018 Feb |
1 |
| 17 |
29055041 | The possible clinical impact of risperidone on P-glycoprotein-mediated transport of tacrolimus: A case report and in vitro study. | 2018 Jan |
1 |
| 18 |
30167757 | Voriconazole greatly increases the exposure to oral buprenorphine. | 2018 Dec |
2 |
| 19 |
27432796 | CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. | 2017 Feb |
1 |
| 20 |
27822915 | Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. | 2017 Mar |
1 |
| 21 |
27937048 | Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes. | 2017 Dec |
2 |
| 22 |
28182291 | Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped. | 2017 Aug |
1 |
| 23 |
28370390 | Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. | 2017 Sep |
3 |
| 24 |
28455946 | Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole. | 2017 Aug |
2 |
| 25 |
28674358 | Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. | 2017 |
2 |
| 26 |
26502771 | Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature. | 2016 Jan |
1 |
| 27 |
27236320 | Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. | 2016 Dec |
3 |
| 28 |
25417855 | Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient. | 2015 Feb |
1 |
| 29 |
25515945 | Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. | 2015 Apr |
6 |
| 30 |
25599164 | Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. | 2015 Mar |
1 |
| 31 |
25868557 | Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism. | 2015 Jun |
2 |
| 32 |
24757038 | Iatrogenic cushing syndrome secondary to a probable interaction between voriconazole and budesonide. | 2014 Jul |
2 |
| 33 |
25120580 | Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity. | 2014 |
1 |
| 34 |
25429674 | Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. | 2014 |
4 |
| 35 |
23653047 | A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. | 2013 Sep |
2 |
| 36 |
23766489 | Steady-state pharmacokinetics and metabolism of voriconazole in patients. | 2013 Nov |
1 |
| 37 |
22106961 | Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. | 2012 May |
4 |
| 38 |
22381043 | Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. | 2012 Nov |
1 |
| 39 |
21937987 | Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. | 2011 Nov |
1 |
| 40 |
19841059 | In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. | 2010 Jan |
1 |
| 41 |
19898510 | Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. | 2010 Jun |
1 |
| 42 |
20175821 | Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. | 2010 Feb |
1 |
| 43 |
20642349 | Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. | 2010 Oct |
2 |
| 44 |
20669013 | Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. | 2010 Nov |
2 |
| 45 |
18777173 | Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. | 2009 Jan |
1 |
| 46 |
18836708 | Voriconazole drastically increases exposure to oral oxycodone. | 2009 Mar |
1 |
| 47 |
19029318 | Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. | 2009 Feb |
5 |
| 48 |
19033450 | CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. | 2009 Feb |
1 |
| 49 |
19916995 | Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole. | 2009 Nov |
1 |
| 50 |
20002085 | Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. | 2009 Dec |
1 |